The global atrial fibrillation market size was US$ 1944.53 million in 2021. The global atrial fibrillation market size is forecast to reach US$ 3,470.70 million by 2030, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period from 2022 to 2030. 

Atrial fibrillation (AF) is an arrhythmia of the heart due to irregular electrical activity in the atria. It may occur without any symptoms, but the most common ones are fainting, palpitations, congestive heart failure, and chest pain. In order to confirm AF, an electrocardiogram must show an absence of the P wave and an irregular rate of ventricular contractions. The irregularities in the regular cardio-electric impulses of the sino-atrial node are the result of the interference of chaotic electrical impulses originating from roots of pulmonary veins, therefore leading to irregular heartbeats.

Factors Influencing Market Growth

• The global atrial fibrillation market is growing due to a higher incidence of the disease among the elderly, technical developments, and a preference for catheter ablation for cardiac arrhythmia treatment. 
• A shortage of experienced specialists and a preference for pharmacological treatments (drugs) over devices to treat atrial fibrillation may slow down the overall market growth.
• The increasing incidence of chronic heart diseases such as hypertension, obesity, and diabetes are driving growth in the global market.

Impact Analysis of COVID-19

The COVID-19 pandemic has caused panic among people suffering from heart diseases. Despite COVID-19's predominant symptoms in the respiratory tract, cardiovascular diseases and complications frequently accompany COVID-19 infections, leading to increased mortality and morbidity. Patients with COVID-19 are frequently diagnosed with arrhythmias, with atrial fibrillation (AF) being the most prevalent form. In addition, people with co-morbidities such as atrial fibrillation are at greater risk of developing medical problems from the virus. The COVID-19 patients with atrial fibrillation are elderly, more hypertensive, and more likely to have a critical status. atrial fibrillation is associated with a 4-fold higher mortality rate in COVID-19 patients, which leads to an increase in demand. Therefore, the COVID-19 pandemic has positively impacted the global market growth.

Regional Insights 

North America accounted for the highest revenue in the atrial fibrillation market in 2021. North American countries are the leader in adopting technologically advanced atrial fibrillation treatments, which drives the growth of the atrial fibrillation market. Additionally, the rapid rise in cardiac diseases in the aging population is increasing the demand for atrial fibrillation. Thus, these factors are fueling the market growth in the region. 

Leading Competitors

The leading prominent companies profiled in the global atrial fibrillation market are:

• Johnson & Johnson
• MicroPort Scientific Corporation
• Boston Scientific Corporation
• St. Jude Medical, Incorporated
• Medtronic plc
• Abbott Laboratories
• Biotronik SE & Co. KG
• Koninklijke Philips N.V.
• Siemens AG
• AtriCure Incorporated
• Other Prominent Players

Scope of the Report

The global atrial fibrillation market segmentation focuses on Type, Technology, End-User, and Region.

Segmentation based on Type

• Surgical
• Non-Surgical

Segmentation based on Technology

• Radiofrequency
• Laser
• Cryotherapy
• Others

Segmentation based on End-User

• Hospitals
• Specialty Clinics
• Others

Segmentation based on Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA
• South America
• Brazil
• Argentina
• Rest of South America